HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mariana Da Silva Ferreira Selected Research

ASN007

1/2021ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mariana Da Silva Ferreira Research Topics

Disease

2Neoplasms (Cancer)
01/2021 - 01/2021
1Lymphoma (Lymphomas)
01/2021
1Melanoma (Melanoma, Malignant)
01/2021
1Weight Loss (Weight Reduction)
01/2021
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2021
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
12/2019
1Hematologic Neoplasms (Hematological Malignancy)
12/2019
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/2019

Drug/Important Bio-Agent (IBA)

1venetoclaxIBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2021
1ASN007IBA
01/2021
1Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA
01/2021
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021
1S63845IBA
01/2021
1P-SelectinIBA
01/2021

Therapy/Procedure

2Therapeutics
01/2021 - 12/2019